Brouwer E - Search Results

1

Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.

van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K, Stoter G, Sparreboom A. van Zuylen L, et al. Among authors: brouwer e. Cancer Chemother Pharmacol. 2001 Apr;47(4):309-18. doi: 10.1007/s002800000215. Cancer Chemother Pharmacol. 2001. PMID: 11345647 Clinical Trial.

2

Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.

de Vos AI, Nooter K, Verweij J, Loos WJ, Brouwer E, de Bruijn P, Ruijgrok EJ, van der Burg ME, Stoter G, Sparreboom A. de Vos AI, et al. Among authors: brouwer e. Ann Oncol. 1997 Nov;8(11):1145-50. doi: 10.1023/a:1008215720081. Ann Oncol. 1997. PMID: 9426335 Free article.

3

Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions.

Brouwer E, Verweij J, Hauns B, Loos WJ, Nooter K, Mross K, Stoter G, Sparreboom A. Brouwer E, et al. Anal Biochem. 1998 Aug 1;261(2):198-202. doi: 10.1006/abio.1998.2746. Anal Biochem. 1998. PMID: 9716422

4

Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.

Sparreboom A, Verweij J, van der Burg ME, Loos WJ, Brouwer E, Viganò L, Locatelli A, de Vos AI, Nooter K, Stoter G, Gianni L. Sparreboom A, et al. Among authors: brouwer e. Clin Cancer Res. 1998 Aug;4(8):1937-42. Clin Cancer Res. 1998. PMID: 9717822

5

Irinotecan (CPT-11) metabolism and disposition in cancer patients.

Sparreboom A, de Jonge MJ, de Bruijn P, Brouwer E, Nooter K, Loos WJ, van Alphen RJ, Mathijssen RH, Stoter G, Verweij J. Sparreboom A, et al. Among authors: brouwer e. Clin Cancer Res. 1998 Nov;4(11):2747-54. Clin Cancer Res. 1998. PMID: 9829738 Clinical Trial.

6

Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.

Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J. Sparreboom A, et al. Among authors: brouwer e. Cancer Res. 1999 Apr 1;59(7):1454-7. Cancer Res. 1999. PMID: 10197613

7

Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.

Gelderblom H, Verweij J, Brouwer E, Pillay M, de Bruijn P, Nooter K, Stoter G, Sparreboom A. Gelderblom H, et al. Among authors: brouwer e. Drug Metab Dispos. 1999 Nov;27(11):1300-5. Drug Metab Dispos. 1999. PMID: 10534315

8

Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.

van Zuylen L, Gianni L, Verweij J, Mross K, Brouwer E, Loos WJ, Sparreboom A. van Zuylen L, et al. Among authors: brouwer e. Anticancer Drugs. 2000 Jun;11(5):331-7. doi: 10.1097/00001813-200006000-00003. Anticancer Drugs. 2000. PMID: 10912949 Clinical Trial.

9

Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.

van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A. van Zuylen L, et al. Among authors: brouwer e. Clin Cancer Res. 2000 Jul;6(7):2598-603. Clin Cancer Res. 2000. PMID: 10914699

10

Measurement of fraction unbound paclitaxel in human plasma.

Brouwer E, Verweij J, De Bruijn P, Loos WJ, Pillay M, Buijs D, Sparreboom A. Brouwer E, et al. Drug Metab Dispos. 2000 Oct;28(10):1141-5. Drug Metab Dispos. 2000. PMID: 10997930 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

463 results

Search Page